Skip to main content

Table 2 The associations of endocrine AEs with different immunotherapy regimens*

From: Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system

Strategy

Drug

N

IC

IC025

IC975

ROR

ROR025

ROR975

Total

Total ICIs

6260

2.53

2.49

2.57

6.14

5.99

6.30

Monotherapy

Anti-PD-1

3398

2.26

2.20

2.31

4.99

4.82

5.16

Nivolumab

2219

2.24

2.17

2.31

4.90

4.70

5.12

Pembrolizumab

1175

2.29

2.19

2.39

5.07

4.78

5.38

Cemiplimab

4

1.60

−0.31

3.50

3.07

1.13

8.32

Anti-PD-L1

269

1.68

1.48

1.88

3.26

2.89

3.68

Atezolizumab

175

1.54

1.29

1.79

2.95

2.54

3.43

Avelumab

27

1.66

1.01

2.31

3.22

2.20

4.73

Durvalumab

67

2.07

1.66

2.47

4.31

3.37

5.49

Anti-CTLA-4

708

2.97

2.84

3.09

8.29

7.68

8.95

Ipilimumab

706

2.97

2.84

3.09

8.30

7.69

8.96

Tremelimumab

2

1.55

−1.49

4.59

2.98

0.72

12.33

Anti-CTLA-4 vs anti-PD-1

 

708

   

1.68

1.55

1.83

Anti-CTLA-4 vs anti-PD-L1

 

708

   

2.54

2.20

2.93

Polytherapy

Polytherapy1

64

4.41

4.00

4.83

25.60

19.44

33.71

Polytherapy2

1664

3.15

3.07

3.24

9.58

9.11

10.07

Polytherapy3

109

4.05

3.73

4.36

18.93

15.45

23.20

Polytherapy4

27

3.96

3.31

4.61

17.68

11.67

26.78

Polytherapy vs. Monotherapy

 

1864

   

2.00

1.89

2.11

  1. *In Table 2, bold text denotes significant signals. Polytherapy1: Nivolumab+ pembrolizumab+ ipilimumab; Polytherapy2: Nivolumab+ ipilimumab; Polytherapy3: Pembrolizumab+ ipilimumab; Polytherapy4: Durvalumab+ tremelimumab. N: number of records; IC025: the lower end of the 95% confidence interval of IC. IC975: the upper end of the 95% confidence interval of IC. ROR025: the lower end of the 95% confidence interval of ROR. ROR975: the upper end of the 95% confidence interval of IC
Back to article page